Correct classification of breast cancer subtypes is of high importance as it directly affects the therapeutic options. We focus on triple-negative breast cancer which has the worst prognosis among breast cancer types. Using cutting edge methods from the field of robust statistics, we analyze Breast Invasive Carcinoma transcriptomic data publicly available from The Cancer Genome Atlas data portal. Our analysis identifies statistical outliers that may correspond to misdiagnosed patients. Furthermore, it is illustrated that classical statistical methods may fail to identify outliers due to their heavy influence, prompting the need for robust statistics. Using robust sparse logistic regression we obtain 36 relevant genes, of which ca. 60% have ...
Triple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavior and disti...
International audienceINTRODUCTION: Triple-negative breast cancers need to be refined in order to id...
Triple-negative breast cancer (TNBC) patients exhibiting pathological complete response (pCR) have b...
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attributio...
Background: Triple-negative breast cancer (TNBC) accounts for 12–20% of all breast cancers. Diagnosi...
BACKGROUND: Triple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavi...
Background: Triple-negative breast cancer (TNBC) accounts for 12–20% of all breast cancers. Diagnosi...
Background: Breast cancer is the most common type of cancer among women and is classified into multi...
Background: Learning accurate models from ‘omics data is bringing many challenges due to their in...
Breast cancer is a heterogeneous disease usually including four molecular subtypes such as luminal A...
Background: Triple-negative breast cancer (TNBC) accounts for 12–20% of all breast cancers. Diagnosi...
The molecular complexity of triple-negative breast cancers (TNBCs) provides a challenge for patient ...
Breast cancer is a heterogeneous disease usually including four molecular subtypes such as luminal A...
NoTriple-negative breast cancers (TNBC) are clinically heterogeneous, an aggressive form of breast c...
As the field of translational ‘omics has progressed, refined classifiers at both genomic and proteom...
Triple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavior and disti...
International audienceINTRODUCTION: Triple-negative breast cancers need to be refined in order to id...
Triple-negative breast cancer (TNBC) patients exhibiting pathological complete response (pCR) have b...
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attributio...
Background: Triple-negative breast cancer (TNBC) accounts for 12–20% of all breast cancers. Diagnosi...
BACKGROUND: Triple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavi...
Background: Triple-negative breast cancer (TNBC) accounts for 12–20% of all breast cancers. Diagnosi...
Background: Breast cancer is the most common type of cancer among women and is classified into multi...
Background: Learning accurate models from ‘omics data is bringing many challenges due to their in...
Breast cancer is a heterogeneous disease usually including four molecular subtypes such as luminal A...
Background: Triple-negative breast cancer (TNBC) accounts for 12–20% of all breast cancers. Diagnosi...
The molecular complexity of triple-negative breast cancers (TNBCs) provides a challenge for patient ...
Breast cancer is a heterogeneous disease usually including four molecular subtypes such as luminal A...
NoTriple-negative breast cancers (TNBC) are clinically heterogeneous, an aggressive form of breast c...
As the field of translational ‘omics has progressed, refined classifiers at both genomic and proteom...
Triple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavior and disti...
International audienceINTRODUCTION: Triple-negative breast cancers need to be refined in order to id...
Triple-negative breast cancer (TNBC) patients exhibiting pathological complete response (pCR) have b...